Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. Sixteen research ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...

Securities exhibited confidence in Axsome Therapeutics (NASDAQ:AXSM) by increasing the company's price target from $137.00 to $195.00. The firm has maintained an Outperform rating on the stock. This ...

Highlights,Axsome Therapeutics stock reached a new 52-week high following an updated price target from financial ...

Axsome Therapeutics Inc is a pharmaceutical company in the United States. It focuses on developing novel therapeutics for the redressal of diseases related to the central nervous system.